Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells Via the Akt/GSK3β/β-Catenin Signaling Axis

Shuang Dai; Yuanliang Yan; Zhijie Xu; Shuangshuang Zeng; Long Qian; Lei Huo; Xuejun Li; Lunquan Sun; Zhicheng Gong

doi:10.3389/fphar.2019.01358

Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells Via the Akt/GSK3β/β-Catenin Signaling Axis

Front Pharmacol. 2019 Nov 15:10:1358. doi: 10.3389/fphar.2019.01358. eCollection 2019.

Authors

Shuang Dai^{1

2

3}, Yuanliang Yan^{1

3}, Zhijie Xu^{1

3

4}, Shuangshuang Zeng^{1

3}, Long Qian^{1

3}, Lei Huo⁵, Xuejun Li⁵, Lunquan Sun⁶, Zhicheng Gong^{1

3}

Affiliations

¹ Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
² School of Pharmaceutical Sciences, Central South University, Changsha, China.
³ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
⁴ Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
⁵ Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
⁶ Center for Molecular Medicine, Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2017.00960.].

Keywords: Akt signaling; SCD1; glioblastomas; resistance; temozolomide.

Publication types

Published Erratum